| Literature DB >> 25254055 |
Lihua Peng1, Li Ren1, Peipei Qin1, Jing Chen1, Ping Feng2, Haidan Lin3, Min Su1.
Abstract
Objectives. To evaluate the comparative analgesia effectiveness and safety of postoperative continuous femoral nerve block (CFNB) with patient controlled intravenous analgesia (PCIA) and their impact on knee function and chronic postoperative pain. Methods. Participants were randomly allocated to receive postoperative continuous femoral nerve block (group CFNB) or intravenous patient controlled analgesia (group PCIA). Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores for knee and incidence of chronic postoperative pain at 3, 6, and 12 months postoperatively were compared. postoperative pain and salvage medication at rest or during mobilization 24 hours, 48 hours, and 7 days postoperatively were also recorded. Results. After discharge from the hospital and rehabilitation of joint function, patients in group CFNB reported significantly improved knee flexion and less incidence of chronic postoperative pain at 3 months and 6 months postoperatively (P < 0.05). Analgesic rescue medications were significantly reduced in patients receiving CFNB (P < 0.001 and P = 0.031, resp.). Conclusion. With standardized rehabilitation therapy, continuous femoral nerve block analgesia reduced the incidence of chronic postoperative pain, improved motility of replaced joints, and reduced the dosages of rescue analgesic medications, suggesting a recovery-enhancing effect of peripheral nerve block analgesia.Entities:
Year: 2014 PMID: 25254055 PMCID: PMC4164420 DOI: 10.1155/2014/569107
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1The regimen of analgesic rescue for patients in both groups. A “three-ladder” analgesic rescue protocol was designed: first, the adjustment of PCA parameters and checking of the femoral catheter in CFNB group; second, use of nonopioid analgesic medications; third, use of opioid analgesic medications. PCA was the abbreviation for patient controlled analgesia, CFNB for continuous femoral nerve block, PCIA for patient controlled intravenous analgesia, and VAS for visual analogue scale.
Baseline Characteristics of eligible patients#.
| Parameters | CFNB ( | PCIA ( |
|
|---|---|---|---|
| Age | 66.81 ± 9.41 | 68.03 ± 11.17 | 0.323 |
| Height (cm) | 158.20 ± 7.69 | 159.41 ± 9.39 | 0.240 |
| Weight (kg) | 62.99 ± 8.38 | 63.17 ± 7.35 | 0.847 |
| WOMAC scores for knee | 53 (51–56) | 54 (51–56) | 0.212△ |
| Surgical time (min) | 87.21 ± 34.23 | 82.37 ± 30.95 | 0.216 |
| Anesthesia time (min) | 125.69 ± 32.62 | 121.08 ± 32.30 | 0.235 |
| Blood loss (mL) | 89.72 ± 93.49 | 88.89 ± 86.27 | 0.939 |
| Tourniquet time (min) | 60.41 ± 29.24 | 56.80 ± 26.92 | 0.284 |
| Gender | |||
| Male/female | 38/102 | 49/91 | 0.156△ |
| American Society of Anesthesiologists (ASA) Grading▲ | |||
| 1 | 19 | 25 | |
| 2 | 59 | 49 | 0.990∗ |
| 3 | 62 | 66 |
#Continuous variables were described as mean ± SD, categorical variables as number of events (n); *Kruskal-Wallis test was used; △Chi square test was used; ▲Wilcoxon rank test was used.
The rest of parameters were compared using independent t-test; statistical significance was considered when P value <0.05.
Preoperative comorbidity of enrolled participants.
| Preoperative comorbidity△ | CFNB group | PCIA group |
|
|---|---|---|---|
|
|
| ||
| Cardiovascular system | |||
| Hypertension | 41/140 (34.2) | 29/140 (24.2) | 0.098 |
| Coronary artery disease | 7/140 (5.8) | 7/140 (5.8) | 1.000 |
| Arrhythmia | |||
| Atrial fibrillation | 1/140 (0.8) | 1/140 (0.8) | 1.000∗ |
| Ventricular premature | 0/140 (0) | 3/140 (2.5) | 0.247∗ |
| Sinus bradycardia | 0/140 (0) | 2/140 (1.7) | 0.498∗ |
| Respiratory system | |||
| Asthma | 2/140 (1.7) | 0/140 (0) | 0.498∗ |
| COPD | 4/140 (3.3) | 8/140 (5.7) | 0.238 |
| Respiratory failure | 1/140 (0.8) | 1/140 (0.8) | 1.000∗ |
| Urological system | |||
| Renal syndrome | 0/140 (0) | 1/140 (0.8) | 0.500∗ |
| Renal failure | 0/140 (0) | 1/140 (0.8) | 0.500∗ |
| Endocrine system and autoimmune disease | |||
| Diabetes | 18/140 (15) | 9/140 (7.5) | 0.068 |
| Rheumatoid arthritis | 0/140 (0) | 3/140 (2.1) | 0.247∗ |
| Thromboembolic events | |||
| Cerebral embolism | 2/140 (1.7) | 0/140 (0) | 0.498∗ |
| Myocardial infraction | 0/140 (0) | 0/140 (0) | |
| Venous thrombosis | 0/140 (0) | 2/140 (1.7) | 0.498∗ |
| Peripheral artery embolism | 0/140 (0) | 0/140 (0) |
△Categorical variables as number of events (n), Chi square test was used; events less than 5 were compared with Fisher's exact test, *P < 0.05.
Figure 2Study flow diagram following the CONSORT statement.
Incidence of chronic postoperative pain after TKA#.
| Intention-to-treat analysis | |||
|---|---|---|---|
| Time points | Group CFNB ( | Group PCIA ( |
|
| 3 months— | 52 (37.1) | 71 (50.7) | 0.022∗ |
| 6 months— | 36 (25.7) | 54 (38.5) | 0.021∗ |
| 12 months— | 5 (3.5) | 9 (6.4) | 0.273 |
|
| |||
| Per-protocol analysis | |||
| Time points | Group CFNB ( | Group PCIA ( |
|
|
| |||
| 3 months— | 52 (47.7) | 71 (68.9) | 0.002∗ |
| 6 months— | 36 (33.0) | 54 (52.4) | 0.004∗ |
| 12 months— | 5 (4.5) | 9 (8.7) | 0.224 |
#Chi-square test was used for comparisons. *P < 0.05.
Incidence of chronic postoperative moderate-to-severe pain in motion#.
| Intention-to-treat analysis | |||
|---|---|---|---|
| Time points | Group CFNB ( | Group PCIA ( |
|
| 3 months— | 38 (27.1) | 47 (33.5) | 0.242 |
| 6 months— | 25 (17.8) | 37 (26.4) | 0.084 |
| 12 months— | 2 (1.4) | 5 (4.3) | 0.251 |
|
| |||
| Per-protocol analysis | |||
| Time points | Group CFNB ( | Group PCIA ( |
|
|
| |||
| 3 months— | 38 (34.8) | 47 (46.0) | 0.047∗ |
| 6 months— | 25 (22.9) | 37 (36.3) | 0.034∗ |
| 12 months— | 2 (1.8) | 5 (4.9) | 0.214 |
#Chi-square test was used for comparisons.*P < 0.05.
Visual analogue scale during hospitalization and postoperatively#.
| Time point | CFNB group | PCIA group |
|
|---|---|---|---|
| VAS scores in motion | |||
| 1 day preoperatively | 5 (4-5) | 5 (4-5) | 0.494 |
| 24 h postoperatively | 3 (3-4) | 3.5 (3-4) | 0.262 |
| 48 h postoperatively | 3 (3-4) | 3 (3-4) | 0.143 |
| 7 days postoperatively | 3 (3-4) | 4 (4-4) | <0.0001∗ |
| 3 months postoperatively | 3 (2–4) | 3 (3-4) | 0.025 |
| 6 months postoperatively | 3 (2-3) | 3 (3-4) | 0.011 |
| 12 months postoperatively | 2 (1–3) | 2 (1–3) | 0.581 |
| VAS scores at rest | |||
| 1 day preoperatively | 2 (1–3) | 2 (1–3) | 0.44 |
| 24 h postoperatively | 3 (3-4) | 3 (3-4) | 0.211 |
| 48 h postoperatively | 3 (3-4) | 3 (3-4) | 0.297 |
| 7 days postoperatively | 3 (2-3) | 3 (3-3) | 0.031∗ |
| 3 months postoperatively | 1 (1-2) | 2 (1–3) | <0.0001 |
| 6 months postoperatively | 1 (1-1) | 2 (1-2) | <0.0001 |
| 12 months postoperatively | 1 (1-1) | 1 (1-1) | 0.681 |
#Continuous variables were described as median (interquartile range) and Wilcoxon rank-sum test was used, *P value <0.05. The total number of patients was 127 in CFNB group and 123 in PCIA group for in-hospital pain evaluation, while 109 patients in CFNB group and 102 patients in PCIA group were included in the analysis of chronic pain.
Doses of analgesic medications of patient controlled analgesia and rescue regimen#.
| Analgesic outcomes | CFNB ( | PCIA ( |
| |
|---|---|---|---|---|
| PCA period | Frequency of bolus | 2.3 ± 0.8 | 2.6 ± 0.7 | 0.003∗ |
| Frequency of rescue | 0.6 ± 0.8 | 1.1 ± 1.3 | 0.002∗ | |
| Mean doses of rescue medication | ||||
| Parecoxib (mg) | 22.4 ± 28.4 | 31.5 ± 34.5 | 0.022∗ | |
| Tramadol (mg) | 5.1 ± 20.7 | 24.0 ± 42.6 | 0.000∗ | |
| Pethidine (mg) | 0 | 0.4 ± 3.2 | 0.158 | |
|
| ||||
| Mean doses of rescue medications | ||||
| Parecoxib (mg) | 963.8 ± 479.0 | 1141.5 ± 259.5 | 0.000∗ | |
| Non-PCA period | Paracetamol (mg) | 166.3 ± 163.1 | 219.3 ± 152.9 | 0.009∗ |
| Tramadol (mg) | 19.2 ± 18.8 | 25.3 ± 17.6 | 0.009∗ | |
| Flurbiprofen (mg) | 7.9 ± 18.3 | 14.2 ± 22.7 | 0.016∗ | |
#Continuous variables were described as mean ± SD and independent t-test was used; *statistical significance was considered when P value <0.05.
Figure 3WOMAC scores for knee before and after surgery. *A significant difference between group CFNB and group PCIA, P < 0.05. WOMAC was the abbreviation for Western Ontario and McMaster Universities Osteoarthritis Index, CFNB for continuous femoral nerve block, and PCIA for patient controlled intravenous analgesia.
Figure 4Degree of flexion for knee before and after surgery. *A significant difference between group CFNB and group PCIA, P < 0.05. CFNB was the abbreviation for continuous femoral nerve block and PCIA for patient controlled intravenous analgesia.
Adverse events related to patient controlled analgesia#.
| Adverse events | CFNB ( | PCIA ( |
|
|---|---|---|---|
| PCA period | |||
| Incomplete analgesia | |||
| In motion | 9 (7.08) | 21 (17.07) | 0.015∗ |
| At rest | 0 (0) | 0 (0) | — |
| Oversedation | 2 (1.57) | 5 (4.06) | 0.275 |
| Nausea and vomiting | 3 (2.36) | 4 (3.25) | 0.719 |
| Respiratory depression | 0 (0) | 2 (1.62) | 0.149 |
| Muscle weakness | 4 (3.14) | 1 (0.81) | 0.370 |
| Catheter thrombosis | 0 (0) | 0 (0) | — |
| Catheter dropout | 0 (0) | 0 (0) | — |
| Local hematoma | 0 (0) | 0 (0) | — |
| Local infection | 0 (0) | 0 (0) | — |
| Non-PCA period | |||
| Incomplete analgesia | 15 (11.8) | 25 (20.3) | 0.066 |
| Oversedation | 0 (0) | 0 (0) | — |
| Nausea and vomiting | 1 (0.78) | 0 (0) | 1.000 |
| Respiratory depression | 0 (0) | 0 (0) | — |
#For events less than 5 in both groups, Fisher's exact test was used; the rest were compared using chi-square test, *Pvalue <0.05.